留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

危重症肝病肝移植患者诊断和评估标准的临床进展

贾亚男 李瀚 李先亮 贺强

贾亚男, 李瀚, 李先亮, 等. 危重症肝病肝移植患者诊断和评估标准的临床进展[J]. 器官移植, 2020, 11(3): 326-332,368. doi: 10.3969/j.issn.1674-7445.2020.03.002
引用本文: 贾亚男, 李瀚, 李先亮, 等. 危重症肝病肝移植患者诊断和评估标准的临床进展[J]. 器官移植, 2020, 11(3): 326-332,368. doi: 10.3969/j.issn.1674-7445.2020.03.002
Jia Yanan, Li Han, Li Xianliang, et al. Clinical progress of diagnostic and evaluation criteria for liver transplantation in patients with severe liver disease[J]. ORGAN TRANSPLANTATION, 2020, 11(3): 326-332,368. doi: 10.3969/j.issn.1674-7445.2020.03.002
Citation: Jia Yanan, Li Han, Li Xianliang, et al. Clinical progress of diagnostic and evaluation criteria for liver transplantation in patients with severe liver disease[J]. ORGAN TRANSPLANTATION, 2020, 11(3): 326-332,368. doi: 10.3969/j.issn.1674-7445.2020.03.002

危重症肝病肝移植患者诊断和评估标准的临床进展

doi: 10.3969/j.issn.1674-7445.2020.03.002
基金项目: 

国家自然科学基金 81571554

国家自然科学基金 81273270

国家自然科学基金 8147159

详细信息
    作者简介:

    贾亚男,女,1992年生,硕士,研究方向为器官移植诱导免疫耐受,Email: 17316117875@yeah.net

    贺强,医学博士,主任医师,教授,博士研究生导师。兼任中国医疗保健国际交流促进会肝脏移植分会主任委员、中华医学会器官移植学分会全国委员、中华医学会器官移植学分会肝移植学组委员、中华医学会外科学分会手术学组委员、中国医师协会器官移植医师分会委员、中国医师协会器官移植医师分会肝移植专业委员会委员、中国医药教育协会腹部肿瘤专业委员会委员,中国医疗保健国际交流促进会软组织肿瘤分会副主任委员、中国医疗保健国际交流促进会胰腺疾病分会委员、中国研究型医院学会移植医学专业委员会常务委员、中国研究型医院学会普通外科学专业委员会委员、北京医学会器官移植学分会常务委员、北京医师协会器官移植专家委员会委员、中国肝移植注册中心科学委员会委员。担任《器官移植》、《中华肝胆外科杂志》、《中华肝脏外科手术学电子杂志》《实用器官移植电子杂志》、《国际移植与血液净化杂志》、《肝癌电子杂志》、《国际外科学杂志》、《Journal of Organ Donation and Transplantation》等杂志编委。在国内外期刊发表学术论文百余篇,先后主持多项国家级及省部级科研课题。长期从事肝移植及肝胆胰肿瘤的临床与基础研究,在肝移植特别是重症肝病肝移植的围手术期管理方面具有丰富的临床经验。对肝胆胰肿瘤的综合诊治具有较深的造诣,擅长肝胆胰肿瘤的各种根治手术,尤其擅长联合血管切除异体血管移植的复杂疑难肝胆胰肿瘤手术以及体外肝切除自体肝移植手术

    通讯作者:

    李先亮,男,1971年生,博士,副主任医师,研究方向为器官移植诱导免疫耐受,Email:lixianliangbjcy@126.com

    贺强,男,1964年生,博士,主任医师,研究方向为器官移植诱导免疫耐受,Email:heqiang349@sina.com

  • 中图分类号: R617, R575.3

Clinical progress of diagnostic and evaluation criteria for liver transplantation in patients with severe liver disease

More Information
  • 摘要: 肝移植是危重症肝病唯一有效的根治手段, 但手术风险高, 围手术期病死率高, 术后并发症高。考虑到供肝短缺及相关手术风险, 需要严格掌握手术指征和移植时机。因此对危重症肝病肝移植的患者进行准确诊断和全面评估病情, 是决定治疗方案的一项重要内容。目前对于危重症肝病的评估标准很多, 除了比较经典的Child-Turcotte-Pugh(CTP)评分和终末期肝病模型(MELD)评分外, 还发展出了许多其它评估标准, 各个移植中心也都有自己的选择, 但并没有一个较为统一的诊断标准, 各评估标准之间也存在争议, 本文即对此进行综述。

     

  • [1] FORTUNE BE, GARCIA-TSAO G, CIARLEGLIO M, et al. Child-Turcotte-Pugh class is best at stratifying risk in variceal hemorrhage: analysis of a US multicenter prospective study[J]. J Clin Gastroenterol, 2017, 51(5): 446-453. DOI: 10.1097/MCG.0000000000000733.
    [2] KAPLAN DE, DAI F, SKANDERSON M, et al. Recalibrating the Child-Turcotte-Pugh score to improve prediction of transplant-free survival in patients with cirrhosis[J]. Dig Dis Sci, 2016, 61(11):3309-3320. DOI: 10.1007/s10620-016-4239-6.
    [3] 姚运海, 甘建和, 赵卫峰.4种评分系统对肝硬化合并感染患者预后的评估价值[J].临床肝胆病杂志, 2019, 35(1):87-91. DOI: 10.3969/j.issn.1001-5256.2019.01.016.

    YAO YH, GAN JH, ZHAO WF. Value of four scoring systems in evaluating the prognosis of cirrhotic patients with infection[J]. J Clin Hepatol, 2019, 35(1):87-91. DOI: 10.3969/j.issn.1001-5256.2019.01.016.
    [4] MALINCHOC M, KAMATH PS, GORDON FD, et al.A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts[J]. Hepatology, 2000, 31(4):864-871. DOI: 10.1053/he.2000.5852.
    [5] KAMATH PS, KIM WR, Advanced Liver Disease Study Group. The model for end-stage liver disease (MELD)[J]. Hepatology, 2007, 45(3):797-805. DOI: 10.1002/hep.21563.
    [6] ARTZNER T, MICHARD B, BESCH C, et al. Liver transplantation for critically ill cirrhotic patients: overview and pragmatic proposals[J]. World J Gastroenterol, 2018, 24(46):5203-5214. DOI: 10.3748/wjg.v24.i46.5203.
    [7] BIGGINS SW. Futility and rationing in liver retransplantation: when and how can we say no?[J]. J Hepatol, 2012, 56(6):1404-1411. DOI: 10.1016/j.jhep. 2011.11.027.
    [8] PENG Y, QI X, GUO X. Child-Pugh Versus MELD score for the assessment of prognosis in liver cirrhosis: a systematic review and Meta-analysis of observational studies[J]. Medicine (Baltimore), 2016, 95(8):e2877. DOI: 10.1097/MD.0000000000002877.
    [9] 韩怡, 胡乃中. MELD、MESO、iMELD对失代偿期肝硬化患者短期预后的评估价值[J].中国现代医学杂志, 2018, 28(16):113-116. DOI: 10.3969/j.issn.1005-8982.2018. 16.023.

    HAN Y, HU NZ. Value of MELD, MESO and iMELD in evaluation of short-term prognosis of patients with decompensated liver cirrhosis[J]. Chin J Mod Med, 2018, 28(16):113-116. DOI: 10.3969/j.issn.1005-8982.2018. 16.023.j.issn.1005-8982.2018.16.023.
    [10] KIM WR, BIGGINS SW, KREMERS WK, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list[J]. N Engl J Med, 2008, 359(10):1018-1026. DOI: 10.1056/NEJMoa0801209.
    [11] RUF AE, KREMERS WK, CHAVEZ LL, et al. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone[J]. Liver Transpl, 2005, 11(3):336-343. DOI: 10.1002/lt.20329.
    [12] 舒梦妮, 李树臣.血清钠对肝硬化失代偿期患者并发症的影响[J].肝脏, 2016, 21(1):6-8. DOI: 10.3969/j.

    issn.1008-1704.2016.01.003. SHU MN, LI SC. Effect of serum sodium on complications in patients with decompensated liver cirrhosis[J]. Chin Hepatol, 2016, 21(1):6-8. DOI: 10.3969/j.issn. 1008- 1704.2016.01.003.
    [13] 陈培鸿, 付淑红.血清钠终末期肝病模型(MELD-Na)评分对肝硬化患者血脂和短期预后的作用分析[J].临床合理用药杂志, 2019, 12(17):121-122. DOI: 10.15887/j.

    cnki.13-1389/r.2019.17.080. CHEN PH, FU SH. Effect analysis of serum sodium in model for end-stage liver disease (MELD-Na) score on blood lipid and short-term prognosis in patients with liver cirrhosis[J]. Chin J Clin Rational Drug Use, 2019, 12(17):121-122. DOI: 10.15887/r.2019.17.080.
    [14] HUO TI, WANG YW, YANG YY, et al. Model for end-stage liver disease score to serum sodium ratio index as a prognostic predictor and its correlation with portal pressure in patients with liver cirrhosis[J]. Liver Int, 2007, 27(4):498-506. DOI: 10.1111/j.1478- 3231.2007.01445.x.
    [15] 龙骏, 林世德, 刘璐璐, 等. MELD相关评分模型对重症化慢性乙型肝炎患者进展为肝衰竭的预测价值[J].中国医学创新, 2019, 16(33):153-157. DOI: 10.3969/j.

    issn.1674-4985.2019.33.039. LONG J, LIN SD, LIU LL, et al. Predictive value of MELD-based models for liver failure in patients with acute exacerbation of chronic hepatitis B patients[J]. Med Innov Chin, 2019, 16(33):153-157. DOI: 10.3969/j.issn.1674-4985.2019.33.039.
    [16] 吴吉圆, 张冬琴, 刘菲菲, 等.病毒性肝炎肝硬化失代偿期患者评分系统对短期预后的分析[J/CD].中国肝脏病杂志(电子版), 2017, 9(1):54-60.DOI: 10.3969/j.issn.1674-7380.2017.01.012.

    WU JY, ZHANG DQ, LIU FF, et al. Assessment of score systems for short-term prognosis of patients with hepatitis virus-related decompensated cirrhosis[J/CD]. Chin J Liver Dis (Electr Vers), 2017, 9(1):54-60. DOI: 10.3969/j.issn.1674-7380.2017.01.012.j.issn.1674-7380.2017.01.012.
    [17] 张志华, 巩晓欢, 韩永荣, 等. Child-Pugh、MELD、MELD-Na和iMELD评分对乙型肝炎肝硬化患者3个月和1年生存率的评估价值[J].胃肠病学, 2018, 23(1):24-28. DOI: 10.3969/j.issn.1008-7125.2018.01.006.

    ZHANG ZZ, GONG XH, HAN YR, et al. Predictive Value of Child-Pugh, MELD, MELD-Na and iMELD score in assessing 3-month and 1-year survival rates in patients with hepatitis B cirrhosis[J]. Chin J Gastroenter, 2018, 23(1):24-28. DOI: 10.3969/j.issn.1008-7125.2018.01.006.
    [18] 陈铿, 曹欣, 郑茵, 等.MELD-Na与CTP评分评估乙型肝炎慢加急性肝衰竭短期预后的对比研究[J].中华肝脏病杂志, 2014, 22(11):801-805. DOI: 10.3760/cma.j.issn.1007-3418.2014.11.001.

    cma.j.issn.1007-3418.2014.11.001. CHEN K, CAO X, ZHENG Y, et al. Comparative study of the MELD-Na and Child-Turcotte-Pugh scores as shortterm prognostic indicators of acute-on-chronic hepatitis B liver failure[J]. Chin J Hepatol, 2014, 22(11):801-805. DOI: 10.3760/cma.j.issn.1007-3418.2014.11.001.
    [19] SALDAÑA RS, SCHREM H, BARTHOLD M, etal. Prognostic abilities and quality assessment of models for the prediction of 90-day mortality in liver transplant waiting list patients[J]. PLoS One, 2017, 12(1):e0170499. DOI: 10.1371/journal.pone.0170499.
    [20] ANNAMALAI A, HARADA MY, CHEN M, et al. Predictors of mortality in the critically ill cirrhotic patient: is the model for end-stage liver disease enough?[J]. J Am Coll Surg, 2017, 224(3):276-282. DOI: 10.1016/j.jamcollsurg.2016.11.005.
    [21] 姜明建, 范蔚芳, 林淑媛.人工肝血浆置换联合血液滤过对妊娠中晚期重症肝病患者临床指标和生存率的影响[J].肝脏, 2018, 23(10):892-894. DOI: 10.3969/j.issn.1008-1704.2018.10.016.

    JIANG MJ, FAN WF, LIN SY. Effect of artificial liver plasma exchange combined with hemofiltration on clinical indexes and survival rate of patients with severe liver disease in the middle and late pregnancy[J]. Chin Hepatol, 2018, 23(10):892-894. DOI: 10.3969/j.issn.1008-1704.2018.10.016.
    [22] 胡月云, 刘波普, 颜君, 等. APACHE Ⅳ评分和MELD评分对肝移植术后患者死亡分辨能力研究[J/CD].中华肝脏外科手术学电子杂志, 2013, 2(5): 314-317. DOI: 10.3877/cma.j.issn.2095-3232.2013.05.010.

    HU YY, LIU BP, YAN J, et al. Discriminability of acute physiology and chronic health evaluation Ⅳ and model for end-stage liver disease scores on mortality after liver transplantation[J/CD]. Chin J Hepatic Surg (Electr Edit), 2013, 2(5): 314-317. DOI: 10.3877/cma.j.issn.2095-3232.2013.05.010.
    [23] MCPHAIL MJ, FARNE H, SENVAR N, et al. Ability of King's College criteria and model for end-stage liver disease scores to predict mortality of patients with acute liver failure: a Meta-analysis[J]. Clin Gastroenterol Hepatol, 2016, 14(4):516-525. DOI: 10.1016/j.cgh.2015. 10.007.
    [24] 韩璞青, 孙嫣. MELD、MELD-Na评分及KCH标准对妊娠期急性肝衰竭患者预后的评估价值[J].临床肝胆病杂志, 2018, 34(7):1508-1513. DOI: 10.3969/j.issn.1001-5256.2018.07.028.

    issn.1001-5256.2018.07.028. HAN PQ, SUN Y. Value of MELD score, MELD-Na score, and King's College Hospital criteria in evaluating the prognosis of patients with acute liver failure of pregnancy[J].J Clin Hepatol, 2018, 34(7):1508-1513. DOI: 10.3969/j.issn.1001-5256.2018.07.028.
    [25] BERNAL W, WILLIAMS R. Beyond KCH selection and options in acute liver failure[J]. Hepatol Int, 2018, 12(3):204-213. DOI: 10.1007/s12072-018-9869-7.
    [26] BAILEY B, AMRE DK, GAUDREAULT P. Fulminant hepatic failure secondary to acetaminophen poisoning: a systematic review and Meta-analysis of prognostic criteria determining the need for liver transplantation[J]. Crit Care Med, 2003, 31(1):299-305. DOI: 10.1097/00003246- 200301000-00048.
    [27] 丁蕊, 赵红, 闫杰, 等.慢加急性肝衰竭的定义及治疗进展[J/CD].中国肝脏病杂志(电子版), 2018, 10(1): 1-5. DOI: 10.3969/j.issn.1674-7380.2018.01.001.

    DING R, ZHAO H, YAN J, et al. Defination and treatment progress of acute-on-chronic liver failure [J/CD]. Chin J Liver Dis (Electr Vers), 2018, 10(1): 1-5. DOI: 10.3969/j.issn.1674-7380.2018.01.001.
    [28] DUSEJA A, CHOUDHARY NS, GUPTA S, et al. APACHE Π score is superior to SOFA, CTP and MELD in predicting the short-term mortality in patients with acute-on-chronic liver failure (ACLF)[J]. J Dig Dis, 2013, 14(9):484-490. DOI: 10.1111/1751-2980.12074.
    [29] ZHOU XD, CHEN QF, WANG ZX, et al. Acute circulatory failure-chronic liver failure-sequential organ failure assessment score: a novel scoring model for mortality risk prediction in critically ill cirrhotic patients with acute circulatory failure[J]. Eur J Gastroenterol Hepatol, 2017, 29(4):464-471. DOI: 10.1097/MEG.0000000000000817.
    [30] SUN DQ, ZHENG CF, LIU WY, et al. AKI-CLIF-SOFA: a novel prognostic score for critically ill cirrhotic patients with acute kidney injury[J]. Aging (Albany NY), 2017, 9(1):286-296. DOI: 10.18632/aging.101161.
    [31] DIRCHWOLF M, RUF AE. Role of systemic inflammation in cirrhosis: from pathogenesis to prognosis[J]. World J Hepatol, 2015, 7(16):1974-1981. DOI: 10.4254/wjh.v7.i16.1974.
    [32] 陈卉, 谭诗云. MELD评分联合NLR预测肝硬化患者短期预后的价值[J].医学研究杂志, 2019, 48(5):143- 147. DOI: 10.11969/j.issn.1673-548X.2019.05.034.

    CHEN H, TAN SY. Value of MELD score combined with NLR in predicting the short-term prognosis of patients with liver cirrhosis[J]. J Med Res, 2019, 48(5):143-147. DOI: 10.11969/j.issn.1673-548X.2019.05.034.
    [33] 杨君, 黄洋辉.血清MMP-2, AFP与MELD评分对HBV相关慢加急性肝衰竭患者预后的评估价值[J].临床与病理杂志, 2019, 39(8):1648-1653. DOI: 10.3978/j.

    issn.2095-6959.2019.08.006. YANG J, HUANG YH. Value of serum MMP-2, AFP and MELD score in prognosis assessment of patients with HBV-related acute on chronic liver failure[J]. Int J Pathol Clin Med, 2019, 39(8):1648-1653. DOI: 10.3978/j.issn.2095-6959.2019.08.006.
    [34] PINATO DJ, SHARMA R, ALLARA E, et al. The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma[J]. J Hepatol, 2017, 66(2):338-346. DOI: 10.1016/j.jhep.2016.09.008.
    [35] HIRAOKA A, KUMADA T, KUDO M, et al. AlbuminBilirubin (ALBI) grade as part of the evidence-based clinical practice guideline for HCC of the Japan society of hepatology: a comparison with the liver damage and Child-Pugh classifications[J]. Liver Cancer, 2017, 6(3):204-215. DOI: 10.1159/000452846.
    [36] 吴坤亮, 张英, 黄晶, 等.终末期肝病模型评分联合吲哚菁绿清除实验预测HBV相关慢加急性肝衰竭预后[J].中山大学学报(医学版), 2018, 39(6):935-940. http://d.old.wanfangdata.com.cn/Periodical/zsykdxxb201806020

    WU KL, ZHANG Y, HUANG J, et al. Model for endstage liver disease combined with indocyanine green clearance test can effectively predict the prognosis of HBV-associated acute-on-chronic liver failure[J]. J Sun Yat-sen Univ (Med Sci), 2018, 39(6):935-940. http://d.old.wanfangdata.com.cn/Periodical/zsykdxxb201806020
    [37] 吕佳昱, 韩涛.关注重症肝病临床管理的热点问题[J].临床肝胆病杂志, 2017, 33(9):1617-1620. DOI: 10.3969/j.issn.1001-5256.2017.09.001.

    LYU JY, HAN T. Hotspots in clinical management of severe liver diseases[J]. J Clin Hepatol, 2017, 33(9):1617- 1620. DOI: 10.3969/j.issn.1001-5256.2017.09.001.
    [38] JASSERON C, FRANCOZ C, ANTOINE C, et al. Impact of the new MELD-based allocation system on waiting list and post-transplant survival - a cohort analysis using the French national CRISTAL database[J]. Transpl Int, 2019, DOI: 10.1111/tri.13448 [Epubahead of print].
    [39] PARIKH ND, AGOPIAN VG. Moving toward personalizing MELD exceptions in liver transplantation for hepatocellular carcinoma[J]. Am J Transplant, 2019, 19(8):2153-2154. DOI: 10.1111/ajt.15389.
    [40] GINÈS P, FERNÁNDEZ J, DURAND F, et al. Management of critically-ill cirrhotic patients[J]. J Hepatol, 2012, 56 (Suppl 1):S13-S24. DOI: 10.1016/S0168-8278(12)60003-8.
  • 加载中
计量
  • 文章访问数:  66
  • HTML全文浏览量:  26
  • PDF下载量:  8
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-02-15
  • 网络出版日期:  2021-01-19
  • 刊出日期:  2020-05-15

目录

    /

    返回文章
    返回